title: Core promoter mutations of hepatitis B virus for the response to interferon in e antigen-positive chronic hepatitis B.
abstract: OBJECTIVE
  Mutations in the precore region are not always detected in hepatitis B virus (HBV) from patients with chronic hepatitis B who respond to interferon and lose hepatitis B e antigen (HBeAg) from serum. The other mutations may also be responsible for the loss of HBeAg and response.
  
  
  METHODS
  Forty six consecutive patients with HBeAg-positive chronic hepatitis B received recombinant-alpha 2 a interferon (total dose: 702 MU). The mutation for stop codon 28 in the precore region was determined by restriction fragment length polymorphism, and mutations in the core promoter were searched for in five HBV DNA clones propagated from each patient.
  
  
  RESULTS
  HBeAg was cleared at 6 months after interferon in 11 (61%) of 18 patients with the precore mutation and in 12 (43%) of 28 without it. Of these 28 patients, 19 with mutations in the core promoter in all five HBV DNA clones lost HBeAg more frequently than the remaining nine who had at least one clone among the five that lacked such mutations (58 vs 11%, p < 0.05).
  
  
  CONCLUSIONS
  HBeAg-positive patients infected with HBV variants having mutations for an HBeAg-negative phenotype would respond better to interferon by clearing HBeAg from serum. Such mutations may not necessarily be in the precore region but also in the core promoter, which would interfere with the synthesis and secretion of HBeAg either at the translation or transcription level.
authors.affiliation: Department of Gastroenterology, Toshiba General Hospital, Tokyo, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Kanai
authors.forename: M
authors.initials: M
authors.lastname: Kako
authors.forename: T
authors.initials: T
authors.lastname: Aikawa
authors.forename: K
authors.initials: K
authors.lastname: Hino
authors.forename: H
authors.initials: H
authors.lastname: Tsubouchi
authors.forename: Y
authors.initials: Y
authors.lastname: Takehira
authors.forename: S
authors.initials: S
authors.lastname: Iwabuchi
authors.forename: T
authors.initials: T
authors.lastname: Kawasaki
authors.forename: F
authors.initials: F
authors.lastname: Tsuda
authors.forename: H
authors.initials: H
authors.lastname: Okamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Miyakawa
authors.forename: M
authors.initials: M
authors.lastname: Mayumi
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D004279:DNA, Viral / Q000235:genetics; D005260:Female; D006509:Hepatitis B / Q000628:therapy* / Q000821:virology; D006512:Hepatitis B Core Antigens / Q000235:genetics*; D006513:Hepatitis B e Antigens / Q000097:blood*; D006515:Hepatitis B virus / Q000235:genetics*; D006521:Hepatitis, Chronic / Q000628:therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D017354:Point Mutation; D012150:Polymorphism, Restriction Fragment Length; D011401:Promoter Regions, Genetic; D011994:Recombinant Proteins
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D006512:Hepatitis B Core Antigens; D006513:Hepatitis B e Antigens; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins